DO
EW icon

denkapparat Operations’s Edwards Lifesciences EW Stock Holding History

denkapparat Operations’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,494
Closed -$213K – 345
2025
Q4 		$213K Buy
+2,494
New +$205K 0.12% 284

Other funds holding EW

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

denkapparat Operations's EW Position: Q1 2026 in Review

denkapparat Operations sold out of Edwards Lifesciences (EW) in Q1 2026, closing a stake of 2,494 shares — an estimated $213K sold.

denkapparat Operations first reported a position in EW in Q4 2025 and held it in 1 quarter. The position peaked at $213K in Q4 2025. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.

  • denkapparat Operations reported no remaining Edwards Lifesciences position as of Q1 2026 after selling out during the quarter.
  • denkapparat Operations sold 2,494 Edwards Lifesciences shares in Q1 2026, an estimated $213K.
  • denkapparat Operations first reported a position in Edwards Lifesciences in Q4 2025 and held it in 1 quarter.
  • denkapparat Operations's Edwards Lifesciences position peaked at $213K in Q4 2025.
  • 1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on denkapparat Operations's 13F filing for Q1 2026, filed 11 May 2026.